Barbara Pro
Impact in
- Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment
- Dermatology top 0.1%
- Cutaneous lymphoproliferative disorders research
Papers in
-
- Lymphoma Diagnosis and Treatment 210
- Genetics 67
- Chronic Lymphocytic Leukemia Research 67
- Co-authors
- Peter Joseph McLaughlin (83 shared papers)Luis Fayad (86 shared papers)Anas Younes (80 shared papers)Jorge Enrique Romaguera (77 shared papers)Andrei R. Shustov (34 shared papers)Felipe Samaniego (56 shared papers)Maria Alma Rodriguez (62 shared papers)Andre Henri Goy (37 shared papers)
- Journals
- Blood (111 papers)Journal of Clinical Oncology (18 papers)Cancer (18 papers)British Journal of Haematology (17 papers)Transplantation and Cellular Therapy (8 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Barbara Pro
278 papers receiving 12.7k citations
Barbara Pro's Hit Papers
Peers
Comparison fields: 5 of 120
- Pathology and Forensic Medicine 8.5k
- Dermatology 2.1k
- Genetics 2.4k
- Oncology 5.7k
- Immunology 2.7k
Countries citing papers authored by Barbara Pro
This map shows the geographic impact of Barbara Pro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Pro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Pro more than expected).
Fields of papers citing papers by Barbara Pro
This network shows the impact of papers produced by Barbara Pro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Pro. The network helps show where Barbara Pro may publish in the future.
Co-authors
The 25 scholars most cited alongside Barbara Pro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 284 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Hit paper breakdown → | 2012 | 820 |
| 2 | Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project Hit paper breakdown → | 2009 | 598 |
| 3 | Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy Hit paper breakdown → | 2012 | 577 |
| 4 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 554 |
| 5 | Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study Hit paper breakdown → | 2011 | 516 |
| 6 | 2005 | 456 | |
| 7 | 2004 | 452 | |
| 8 | 2013 | 432 | |
| 9 | 2004 | 393 | |
| 10 | 2003 | 214 | |
| 11 | 2010 | 201 | |
| 12 | 2017 | 190 | |
| 13 | 2013 | 187 | |
| 14 | 2003 | 187 | |
| 15 | The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma Hit paper breakdown → | 2021 | 178 |
| 16 | 2014 | 177 | |
| 17 | 2010 | 172 | |
| 18 | 2003 | 170 | |
| 19 | 2006 | 169 | |
| 20 | 2009 | 153 |
About Barbara Pro
Barbara Pro is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Dermatology and Immunology, having authored 284 papers that have together received 13.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (210 papers), Chronic Lymphocytic Leukemia Research (67 papers), Cutaneous lymphoproliferative disorders research (47 papers), T-cell and Retrovirus Studies (43 papers), Viral-associated cancers and disorders (43 papers), CAR-T cell therapy research (34 papers), CNS Lymphoma Diagnosis and Treatment (22 papers) and Histone Deacetylase Inhibitors Research (18 papers). The work is most often cited by research in Pathology and Forensic Medicine (8.5k citations), Dermatology (2.1k citations), Genetics (2.4k citations), Oncology (5.7k citations) and Immunology (2.7k citations). Barbara Pro has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Peter Joseph McLaughlin, Luis Fayad, Anas Younes, Jorge Enrique Romaguera, Andrei R. Shustov, Felipe Samaniego, Maria Alma Rodriguez, Andre Henri Goy, Nam Hoang Dang and Fernando Cabanillas. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, British Journal of Haematology and Transplantation and Cellular Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.